BRPI0910758A2 - composição sólida termoestável, composição farmacêutica, processos para a preparação de uma composição sólida termoestável e de uma composição farmacêutica, método para melhorar a biodisponibilidade de um ingrediente farmaceuticamente ativo, e, produto - Google Patents

composição sólida termoestável, composição farmacêutica, processos para a preparação de uma composição sólida termoestável e de uma composição farmacêutica, método para melhorar a biodisponibilidade de um ingrediente farmaceuticamente ativo, e, produto

Info

Publication number
BRPI0910758A2
BRPI0910758A2 BRPI0910758A BRPI0910758A BRPI0910758A2 BR PI0910758 A2 BRPI0910758 A2 BR PI0910758A2 BR PI0910758 A BRPI0910758 A BR PI0910758A BR PI0910758 A BRPI0910758 A BR PI0910758A BR PI0910758 A2 BRPI0910758 A2 BR PI0910758A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition
solid composition
thermostable solid
thermostable
Prior art date
Application number
BRPI0910758A
Other languages
English (en)
Inventor
Vincent Ket Aldo
Dinter-Heidorn Heike
P Moschwitzer Jan
Original Assignee
Abbott Products Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Products Gmbh filed Critical Abbott Products Gmbh
Publication of BRPI0910758A2 publication Critical patent/BRPI0910758A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0910758A 2008-04-22 2009-04-21 composição sólida termoestável, composição farmacêutica, processos para a preparação de uma composição sólida termoestável e de uma composição farmacêutica, método para melhorar a biodisponibilidade de um ingrediente farmaceuticamente ativo, e, produto BRPI0910758A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08103657 2008-04-22
PCT/EP2009/054720 WO2009130204A2 (en) 2008-04-22 2009-04-21 Improved formulations for poorly permeable active pharmaceutical ingredients

Publications (1)

Publication Number Publication Date
BRPI0910758A2 true BRPI0910758A2 (pt) 2018-03-20

Family

ID=39816874

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910758A BRPI0910758A2 (pt) 2008-04-22 2009-04-21 composição sólida termoestável, composição farmacêutica, processos para a preparação de uma composição sólida termoestável e de uma composição farmacêutica, método para melhorar a biodisponibilidade de um ingrediente farmaceuticamente ativo, e, produto

Country Status (18)

Country Link
US (1) US20090263479A1 (pt)
EP (1) EP2268270A2 (pt)
JP (1) JP5726067B2 (pt)
KR (1) KR20110005883A (pt)
CN (1) CN102119025B (pt)
AR (1) AR071375A1 (pt)
AU (1) AU2009240050A1 (pt)
BR (1) BRPI0910758A2 (pt)
CA (1) CA2720658C (pt)
CO (1) CO6300932A2 (pt)
DO (1) DOP2010000318A (pt)
EA (1) EA032766B1 (pt)
EC (1) ECSP10010514A (pt)
IL (1) IL208370A0 (pt)
MX (1) MX2010011564A (pt)
NZ (1) NZ588369A (pt)
TW (1) TW200948399A (pt)
WO (1) WO2009130204A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
AR071375A1 (es) 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
CN104684545B (zh) 2012-09-27 2018-04-03 巴斯夫欧洲公司 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂
EP2900219B1 (en) 2012-09-27 2016-07-06 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
WO2014122195A1 (en) * 2013-02-06 2014-08-14 Hermes Arzneimittel Gmbh Pharmaceutical compositions incorporating low-dose drugs
WO2015193309A1 (en) * 2014-06-18 2015-12-23 F. Hoffmann-La Roche Ag New pharmaceutical composition comprising non-ionic surfactants
DK3157506T3 (da) 2014-06-20 2020-11-23 Hermes Arzneimittel Gmbh Smagsmaskeret oral, farmaceutisk sammensætning
CN111053755B (zh) * 2019-12-31 2022-03-29 金日制药（中国）有限公司 一种高渗透性的头孢克肟胶囊制剂制备方法
TW202143997A (zh) * 2020-03-18 2021-12-01 大陸商四川海思科製藥有限公司 口服藥物組合物
CN112704649A (zh) * 2020-12-30 2021-04-27 广东臻香荟生物科技有限公司 一种具备抑菌性能的香薰液
JP7368548B2 (ja) * 2021-07-02 2023-10-24 昊運股▲フン▼有限公司 薬学的組成物及びその使用
CN114601800B (zh) * 2021-09-28 2023-07-28 天津瑞普生物技术股份有限公司 一种甲磷丙泊酚钠无菌粉针剂及其制备方法
US20230277464A1 (en) * 2022-03-04 2023-09-07 Abitec Corporation Tablet dosage forms for lipid-based drug delivery systems
WO2023174433A1 (en) * 2022-03-18 2023-09-21 Smart Pharmaceutical (Suzhou) Co., Ltd. Solid, semisolid, or liquid compositions for augmenting the stability, permeability and bioavailability of active pharmaceutical substances

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
US3145146A (en) * 1961-10-31 1964-08-18 Warner Lambert Pharmaceutical Modified mannitol for pharmaceutical tablets
US3477864A (en) * 1965-05-07 1969-11-11 Sumitomo Chemical Co Process for coating pharmaceutical preparations with a hydroxy propyl methyl cellulose-sealing agent moisture-preventing film
US3692543A (en) * 1971-01-28 1972-09-19 Wellman Lord Inc Food products
JPS57171428A (en) * 1981-04-13 1982-10-22 Sankyo Co Ltd Preparation of coated solid preparation
JPH085086B2 (ja) * 1992-07-14 1996-01-24 メリート株式会社 金型装置
DE19709532A1 (de) * 1997-03-10 1998-09-17 Basf Ag Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten zum Überziehen von pharmazeutischen oder agrochemischen Darreichungsformen
FR2790388B1 (fr) * 1999-03-04 2001-04-13 Synthelabo Compositions pharmaceutiques comprenant un benzamide et au moins un promoteur d'absorption
DE19913606A1 (de) * 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
US6692771B2 (en) 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
KR100425226B1 (ko) * 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
MXPA04008100A (es) * 2002-02-21 2005-06-17 Biovail Lab Int Srl Formulaciones de liberacion modificada de al menos una forma de tramadol.
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
US7262184B2 (en) * 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
EP1677770A2 (en) * 2003-10-31 2006-07-12 Dexcel Ltd. Stable lansoprazole formulation
WO2006036614A2 (en) 2004-09-24 2006-04-06 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials comprising vitamin e tpgs and a water soluble polymer
US20060240108A1 (en) * 2005-04-26 2006-10-26 Bernard Bobby L Cellulosic films incorporating a pharmaceutically acceptable plasticizer with enhanced wettability
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline
WO2006133733A1 (en) * 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
WO2007086078A2 (en) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
WO2007092642A2 (en) * 2006-02-09 2007-08-16 Merck & Co., Inc. Polymer formulations of cetp inhibitors
JP2009539862A (ja) 2006-06-09 2009-11-19 メリオン リサーチ Ｉｉｉ リミテッド 強化剤を含む固体経口投与剤形
US7923026B2 (en) * 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
EP2083799A1 (en) * 2006-10-20 2009-08-05 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
AR071375A1 (es) 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto

Also Published As

Publication number Publication date
EA201071218A1 (ru) 2011-06-30
AR071375A1 (es) 2010-06-16
CA2720658A1 (en) 2009-10-29
JP5726067B2 (ja) 2015-05-27
EA032766B1 (ru) 2019-07-31
NZ588369A (en) 2012-06-29
KR20110005883A (ko) 2011-01-19
US20090263479A1 (en) 2009-10-22
CN102119025B (zh) 2014-09-03
WO2009130204A3 (en) 2010-08-05
EP2268270A2 (en) 2011-01-05
IL208370A0 (en) 2010-12-30
JP2011518208A (ja) 2011-06-23
DOP2010000318A (es) 2011-01-15
CN102119025A (zh) 2011-07-06
ECSP10010514A (es) 2010-11-30
TW200948399A (en) 2009-12-01
MX2010011564A (es) 2011-03-02
WO2009130204A2 (en) 2009-10-29
AU2009240050A1 (en) 2009-10-29
CO6300932A2 (es) 2011-07-21
CA2720658C (en) 2016-07-12

Similar Documents

Publication Publication Date Title
BRPI0910758A2 (pt) composição sólida termoestável, composição farmacêutica, processos para a preparação de uma composição sólida termoestável e de uma composição farmacêutica, método para melhorar a biodisponibilidade de um ingrediente farmaceuticamente ativo, e, produto
BRPI0817423A2 (pt) Processos para a preparação de um composto, para a preparação de uma formulação farmacêutica, e para a preparação de um intermediário de um composto, e, composto
HUE037742T2 (hu) Szubsztituált azolok, vírusellenes aktív adalék, gyógyszerészeti készítmény, az elõállításukat célzó eljárás és alkalmazásuk
BR122020011920A2 (pt) composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0816320A2 (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação
PL2451445T3 (pl) Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną
BRPI0914918A2 (pt) forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
IL208203A (en) Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations
WO2010146179A3 (en) Solid pharmaceutical composition comprising rivaroxaban
BRPI0921429A2 (pt) formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
BRPI0922566A2 (pt) polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
BRPI0818680A2 (pt) composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica
WO2011042918A3 (en) Improved processes for preparing prasugrel and pharmaceutically acceptable salts thereof
BRPI1016132A2 (pt) composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável.
BRPI0921507A2 (pt) composição, método de preparação de um excipiente, comprimido farmacêutico e método de preparação do mesmo
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
BRPI0819534A2 (pt) Composição farmacêutica, método para tratar hiv ou aids e método para preparar uma composição farmacêutica, forma de dosagem e composição"
BRPI0922714A2 (pt) composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica
WO2011005052A3 (en) Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
BRPI0807001A2 (pt) Formulação farmacêutica, e, método para preparação de uma formulação farmacêutica.
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2014100735A3 (en) Diazole amides

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.